Compare Enveric Biosciences Inc (ENVB) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Hershey Co — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while Hershey Co trades at $173.3 (market cap $34.54B). The key difference: Hershey Co is far larger — about 6492.5× Enveric Biosciences Inc's market cap, and Hershey Co pays a 3.41% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | HSY | |
|---|---|---|
Market Cap | $5.32M | $34.54B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $236.28 |
52-Week Low | $1.28 | $162.31 |
Enterprise Value | $408.82K | $39.34B |
Dividend Yield | — | 3.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Hershey (HSY) trades at $171.46, down 2.16% on the day, with a bearish technical signal but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.35 exceeding expectations. Revenue growth remains steady, and the company benefits from easing cocoa costs and margin recovery. Recent corporate actions include a $1.45 dividend payment scheduled for June 2026.
The outlook for HSY is cautiously optimistic, driven by margin improvement and innovation, though near-term price pressure and competitive risks persist. The consensus price target of $209.25 suggests upside potential, but investors should monitor execution on H2 2026 guidance and input cost trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
